Nektar Therapeutics (NKTR) Expected to Announce Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) will likely be issuing its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.69) per share and revenue of $10.4390 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Nektar Therapeutics Stock Up 4.4%

NKTR stock opened at $71.11 on Thursday. The firm has a 50 day moving average of $49.49 and a two-hundred day moving average of $51.07. Nektar Therapeutics has a 12 month low of $6.45 and a 12 month high of $75.67. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.92 and a beta of 1.17.

Insider Buying and Selling

In other news, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer directly owned 75,489 shares in the company, valued at $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares of the company’s stock, valued at $761,697.18. This represents a 15.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 4,470 shares of company stock worth $181,955 in the last ninety days. Insiders own 5.25% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

Large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in Nektar Therapeutics during the second quarter valued at about $367,000. OMERS ADMINISTRATION Corp bought a new stake in Nektar Therapeutics in the 4th quarter valued at $304,000. XTX Topco Ltd raised its stake in shares of Nektar Therapeutics by 22.0% in the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 1,299 shares in the last quarter. Opal Capital LLC acquired a new position in shares of Nektar Therapeutics in the 4th quarter valued at $251,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Nektar Therapeutics during the 3rd quarter worth about $234,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Citigroup started coverage on Nektar Therapeutics in a research note on Wednesday, November 26th. They set a “buy” rating and a $102.00 price target for the company. William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Finally, BTIG Research raised their price objective on Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $126.29.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.